Clinical trials: Desmoid
Familial Adenomatous Polyposis (FAP), Attenuated Familial Adenomatous Polyposis (AFAP)
Familial Adenomatous Poliposys Italian Network (Rete Italiana Poliposi Adenomatosa Familiare)
RIPAF (Rete Italiana Poliposi Adenomatosa Familiare) is a national, multicenter observational registry designed to establish a coordinated Italian network for the management of Familial Adenomatous Polyposis (FAP) and related…
- Conditions
- Familial Adenomatous Polyposis (FAP), Attenuated Familial Adenomatous Polyposis (AFAP), MUTYH-Associated Polyposis (MAP), Non-APC/MUTYH Associated Polyposis (NAMP)
- Trial name
- RIPAF (NCT07461246)
- Where
- Italy
- Volunteers
- 1,500 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Desmoid Tumor, Aggressive Fibromatosis
Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)
This study evaluates nirogacestat (PF-03084014) in the treatment of desmoid tumor/aggressive fibromatosis (DT/AF). In the double-blind phase, half of the participants will receive nirogacestat while the other half will receive…
- Trial name
- DeFi (NCT03785964)
- Testing
- Nirogacestat oral tablet
- Where
- 52 sites in United States, Belgium and 5 more
- Volunteers
- 142 people
- Sponsor
- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Desmoid Tumor
Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I/II trial is studying the side effects of imatinib mesylate and to see how well it works…
- Trial name
- NCT00287846
- Testing
- imatinib mesylate
- Where
- 23 sites in France
- Volunteers
- 40 people
- Sponsor
- UNICANCER
Ewing Sarcoma, PEComa
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
This study investigates the safety/toxicity and potential anti-tumor activity of sequential administration of nivolumab and escalating doses of the mammalian target of rapamycin (mTOR) inhibitor nab-rapamycin (ABI-009) in…
- Conditions
- Ewing Sarcoma, PEComa, Epithelioid Sarcoma, Desmoid Tumor
- Trial name
- NCT03190174
- Testing
- Nab-Rapamycin, Nivolumab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Sarcoma Oncology Research Center, LLC
Cancer
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid…
- Trial name
- NCT00020579
- Testing
- entinostat
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Desmoid
Arterial Chemoembolization for the Treatment of Desmoid Fibromatosis
Desmoid fibromatoses are rare (1-2 cases/million per year) and locally aggressive mesenchymal tumors. For asymptomatic disease, current guidelines suggest an initial period of active surveillance.
- Trial name
- Embodesmo (NCT06268457)
- Testing
- Chemoembolization with Doxorubicin
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Istituto Ortopedico Rizzoli
Desmoid Tumor
Study of Cryoablation and Nirogacestat for Desmoid Tumor
The primary purpose of this protocol is Systemic therapy with oral study agent, nirogacestat, followed by a single cryoablation procedure.
- Trial name
- NCT05949099
- Testing
- Nirogacestat, Cryoablation
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Nam Bui
Tumor, Desmoplastic Small Round Cell, Adult, Tumor, Desmoplastic Small Round Cell, Childhood
Trial of Nab-paclitaxel in Patients With Desmoid Tumors and Multiply Relapsed/Refractory Desmoplastic Small Round Cell Tumors and Ewing Sarcoma
A two-cohort, fase II, open-label, non-randomized, multicenter clinical trial. 14 sites in Spain. Cohort 1: Subjects with desmoid tumor (DT) Cohort 2: Subjects with desmoplastic small round cell tumor or Ewing sarcoma (DSRCT and…
- Conditions
- Tumor, Desmoplastic Small Round Cell, Adult, Tumor, Desmoplastic Small Round Cell, Childhood, Sarcoma, Ewing, Sarcoma
- Trial name
- ABRADES (NCT03275818)
- Testing
- nab paclitaxel
- Where
- 7 sites in Spain
- Volunteers
- 69 people
- Sponsor
- Grupo Espanol de Investigacion en Sarcomas
Hernia, Ventral, Intestinal Fistula
RCT of Two Noncrosslinked Porcine Acellular Dermal Matrices in Ab Wall Reconstruction
The purpose of the study is to compare the clinical outcomes of two commonly used, FDA-approved biologic meshes in hernia repair and abdominal wall reconstruction (Strattice and XenMatrix).
- Conditions
- Hernia, Ventral, Intestinal Fistula, Fibromatosis, Abdominal
- Trial name
- NCT02228889
- Testing
- Abdominal wall reconstruction with Strattice, Assess pain intensity at last office visit preoperatively, Assess pain interference at last office visit preoperatively
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Jeffrey Janis
Tumor
Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study
To learn about the safety and effects of an investigational drug called nirogacestat when given to participants with a desmoid tumor/aggressive fibromatosis
- Trial name
- NCT05879146
- Testing
- Nirogacestat
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Desmoid Tumor
A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis
Desmoid-type fibromatosis (or desmoid tumor) represents an intermediate grade neoplasm with a striking predilection for locally invasive growth and recurrence following resection. It occurs in children as well as young adults.
- Trial name
- NCT01265030
- Testing
- Sirolimus
- Where
- 8 sites in United States
- Volunteers
- 9 people
- Sponsor
- MaineHealth
Desmoid Tumor
Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor
This phase II trial is studying how well giving sulindac together with tamoxifen works in treating patients with desmoid tumor. Sulindac may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell…
- Trial name
- NCT00068419
- Testing
- tamoxifen citrate, sulindac, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Children's Oncology Group
Desmoid Tumor, Aggressive Fibromatoses
Patient-reported Outcomes Following Percutaneous Ablation of Desmoid Tumors
This study will evaluate patient-reported outcomes before and after percutaneous ablation of desmoid tumors. Adult participants undergoing ablation for desmoid tumor will complete surveys pre and post procedure to assess symptom…
- Trial name
- NCT07755176
- Testing
- Desmoid tumor ablation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Neoplasm, Desmoid Tumor
Compassionate Use Protocol for PF-03084014 in Patients With Advanced Solid Tumor Malignancies
This is a single-center, open label, non randomized, compassionate use protocol in patients with advanced solid tumor malignancies who were previously enrolled in the phase I study (NCT00878189) of this agent.
- Trial name
- NCT02955446
- Testing
- PF-03084014
- Where
- United States
- Sponsor
- University of Colorado, Denver
Adult Malignant Fibrous Histiocytoma of Bone, Desmoid Tumor
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Adult Malignant Fibrous Histiocytoma of Bone, Desmoid Tumor, Endometrial Cancer, Ovarian Cancer
- Trial name
- NCT00474994
- Testing
- sunitinib malate
- Where
- 2 sites in United States
- Volunteers
- 53 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Desmoid Type-fibromatosis
Toremifene in Desmoid Tumor: Prospective Clinical Trial and Identification of Potential Molecular Targets
This is a prospective study evaluating the activity and the safety of toremifene in patients with primary or recurrent sporadic DTs.
- Trial name
- NCT02353429
- Testing
- Toremifene
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Desmoid
Cryotherapy in the Treatment of Desmoid Tumors
Desmoid tumor is a benign neoplasm with an unpredictable course and a high rate of local recurrence if treated surgically. Therefore, over time the surgical approach has become conservative, preferring simple observation or…
- Trial name
- NCT05091255
- Testing
- Cryotherapy
- Where
- Italy
- Volunteers
- 94 people
- Sponsor
- Istituto Ortopedico Rizzoli
Desmoid Tumor
Vinblastine and Methotrexate in Treating Children With Desmoid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003019
- Testing
- methotrexate, vinblastine sulfate
- Where
- 39 sites in United States, Australia and 1 more
- Volunteers
- 28 people
- Sponsor
- Children's Oncology Group
Desmoid, Desmoid Fibromatosis of Skin
Doxorubicin Eluting Intra-arterial Embolization for Aggressive Desmoid Fibromatosis
In this study Drug-eluting microbeads (DEB) loaded with Doxorubicin will be delivered into the target Desmoid Fibromatoses (DF) tissue via selective arterial embolization by angiographic technique.
- Conditions
- Desmoid, Desmoid Fibromatosis of Skin, Desmoid Neoplasm of Chest Wall, Desmoid Tumor Caused by Somatic Mutation
- Trial name
- NCT03966742
- Testing
- Drug Eluting Bead Embolization (DEB) for Desmoid Fibromatosis
- Where
- Israel
- Volunteers
- 8 people
- Sponsor
- Rabin Medical Center
Desmoid Fibromatosis
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
This randomized phase III trial compares the effects, good and/or bad, of sorafenib tosylate in treating patients with desmoid tumors or aggressive fibromatosis.
- Trial name
- NCT02066181
- Testing
- Laboratory Biomarker Analysis, Quality-of-Life Assessment, Sorafenib Tosylate
- Where
- 150 sites in United States, Canada
- Volunteers
- 87 people
- Sponsor
- National Cancer Institute (NCI)